By Fineline Cube 
Alebund Pharmaceuticals (Jiangsu) Limited (HKG: 9637) successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, raising HKD 1.28 billion (USD 163 million) through the sale of 56,755,400 shares at HKD 22.6 (USD 2.88) per share. The China-based biopharmaceutical company, founded in 2018, focuses exclusively on developing innovative therapies for chronic kidney disease (CKD) and related complications.
Transaction Details
| Item | Detail |
|---|---|
| Company | Alebund Pharmaceuticals (Jiangsu) Limited |
| Stock Code | HKG: 9637 |
| IPO Proceeds | HKD 1.28 billion (USD 163 million) |
| Shares Offered | 56,755,400 |
| Price per Share | HKD 22.6 (USD 2.88) |
| Listing Date | June 2026 |
| Use of Proceeds | Clinical development, regulatory submissions, and commercial preparation |
Pipeline Overview – Seven-Product Portfolio
Core Product – AP301 (Late-Stage)
- Indication: Hyperphosphatemia in dialysis patients with CKD
- Status: Completed Phase III registration trial in China; NDA submission expected imminently
- Global Development: Ongoing multinational Phase III pivotal trial (MRCT) in US and China
- Market Need: Addresses one of the most common and serious complications of CKD in dialysis patients
Lead Clinical Candidate – AP306 (Late-Stage)
- Mechanism: Differentiated pan-phosphate transporter inhibitor
- Partnership: Licensed from Japan’s Chugai Pharmaceutical
- Regulatory Status: Granted Breakthrough Therapy Designation (BTD) by China’s NMPA
- Target Population: Hyperphosphatemia in dialysis patients with CKD
Preclinical Candidates
| Asset | Indication | Key Differentiation | Regulatory Status |
|---|---|---|---|
| AP303 | ADPKD, IgAN, DKD, FSGS | Disease-modifying approach to halt/slow CKD progression | FDA Orphan Drug Designation for ADPKD |
| AP308 | IgA nephropathy (IgAN) | Recombinant IgA protease for functional cure | Technology licensed from Peking University First Hospital |
| AP304, AP305, AP307 | Various CKD subtypes | Early-stage differentiated candidates | Preclinical development |
Strategic Rationale & Market Opportunity
- CKD Market Size: Affects over 850 million people globally with limited disease-modifying treatment options
- Hyperphosphatemia Burden: Impacts approximately 70% of dialysis patients, requiring daily phosphate binder therapy
- Competitive Advantage: AP301 and AP306 offer differentiated mechanisms compared to existing phosphate binders
- Regulatory Catalysts: Multiple near-term opportunities including AP301 NDA submission and AP306 BTD benefits
- Technology Platform: Proprietary approaches spanning small molecules, biologics, and enzyme replacement strategies
The IPO provides Alebund with substantial capital to advance its lead assets through late-stage development and prepare for commercial launch, while maintaining a robust early-stage pipeline addressing diverse aspects of kidney disease pathology.
Competitive Landscape & Differentiation
- AP301: Potential first-in-class phosphate binder with improved tolerability profile compared to current standard of care
- AP306: Only pan-phosphate transporter inhibitor in development with BTD status, potentially offering superior efficacy
- AP303: One of few disease-modifying approaches targeting multiple forms of progressive CKD
- AP308: Novel functional cure strategy for IgAN, a condition with no approved disease-modifying therapies
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory submissions, market opportunities, and use of IPO proceeds. Actual results may differ materially due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market conditions.-Fineline Info & Tech